| Pharmaceutical Information |
| Drug Name |
Abiraterone |
| Drug ID |
BADD_D00014 |
| Description |
Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011. |
| Indications and Usage |
Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. |
| Marketing Status |
approved |
| ATC Code |
L02BX03 |
| DrugBank ID |
DB05812
|
| KEGG ID |
Not Available
|
| MeSH ID |
C089740
|
| PubChem ID |
132971
|
| TTD Drug ID |
D02STN
|
| NDC Product Code |
42291-024; 42291-073; 69238-1754; 60219-1754; 60687-455; 17337-0082; 54893-0070; 30007-838; 69238-1165; 60219-1165 |
| UNII |
G819A456D0
|
| Synonyms |
abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598 |
|
| Chemical Information |
| Molecular Formula |
C24H31NO |
| CAS Registry Number |
154229-19-3 |
| SMILES |
CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
